Drug intelligence / Profile preview

KN015

Development stage: Phase 1
Lead developer: Suzhou Alphamab Co., Ltd.
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

KN015 is a long-acting, recombinant human follicle-stimulating hormone (FSH) Fc fusion protein developed for infertility treatment. It induces follicle development and is designed to require only a single subcutaneous injection in a controlled ovarian stimulation (COS) treatment cycle, compared to multiple injections needed with existing FSH products. In preclinical studies, KN015 demonstrated longer in vivo half-life and similar bioactivity compared to Gonal-F. Phase 1 clinical trials showed that a single dose of KN015 was able to induce follicular growth in healthy, pituitary-suppressed women with a tolerable safety profile.

Targets

FSHR (Follicle-stimulating hormone receptor)

Beyond the preview

Go deeper on KN015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on KN015.

Explore the full profile